Jiang Jia, Chen Lei, Ji Xiaowei, Zheng Xuan, Hong Junjie, Tang Kun, Zheng Xiangwu
Radiological Imaging Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Res Diagn Interv Imaging. 2023 Jan 7;5:100021. doi: 10.1016/j.redii.2022.100021. eCollection 2023 Mar.
To evaluate the diagnostic performance of (F)-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence (BCR) after radical prostatectomy and the effect of (F)-PSMA-1007 PET/CT on treatment strategy.
A total of 114 patients with BCR after radical prostatectomy who performed (F)-PSMA-1007 PET/CT were retrospectively analyzed. The Gleason scores (GS), maximum standardized uptake values (SUV) and the diagnostic performance were compared according to different prostate-specific antigen (PSA) groups. To evaluate the impact of (F)-PSMA-1007 PET/CT on treatment management, we also collected subjects' therapy before and after PET/CT. The PSA value was monitored to evaluate the biochemical response.
(F)-PSMA-1007PET/CT was positive in 92/114 patients (80.7%). The detection rates were 20/34 (58.8%), 13/17 (76.5%), 15/17 (88.2%) and 44/46 (95.7%) for PSA levels of 0.2-<0.5, 0.5-<1, 1-<2, ≥2 ng/ml. The positive lesions on PET/CT revealed local recurrence in 24/114 (21.1%) patients, lymph nodes metastases in 54/114 (47.4%) and metastatic sites in bone, lung, and others in 75/114 (65.8%). A significant positive correlation was observed between the GS/ SUV and PSA level (r = 0.375, r = 0.336, <0.001). As a result of the (F)-PSMA-1007 PET/CT, therapeutic decision-making changed in 60/114 (52.6%) patients. With a follow-up of 11.0 ± 6.4 months, 81/114 PSA were collected after treatment guided by (F)-PSMA-1007 PET/CT, and in 42/81 (51.9%) of patients, serum PSA levels decreased of more than 60%.
(F)-PSMA-1007 PET/CT has a high lesion detection rate for recurrent prostate cancer (PCa) and could have significant implications in decision-making treatment plan for the majority of PCa patients.
评估¹⁸F-PSMA-1007 PET/CT在前列腺癌根治术后生化复发（BCR）患者中的诊断效能以及¹⁸F-PSMA-1007 PET/CT对治疗策略的影响。
回顾性分析114例前列腺癌根治术后发生BCR且接受¹⁸F-PSMA-1007 PET/CT检查的患者。根据不同前列腺特异性抗原（PSA）分组比较Gleason评分（GS）、最大标准化摄取值（SUV）及诊断效能。为评估¹⁸F-PSMA-1007 PET/CT对治疗管理的影响，我们还收集了PET/CT检查前后受试者的治疗情况。监测PSA值以评估生化反应。
¹⁸F-PSMA-1007 PET/CT检查结果阳性的患者有92/114例（80.7%）。PSA水平为0.2<0.5、0.5<1、1~<2、≥2 ng/ml时的检出率分别为²⁰/³⁴（58.8%）、¹³/¹⁷（76.5%）、¹⁵/¹⁷（88.2%）和⁴⁴/⁴⁶（95.7%）。PET/CT上的阳性病变显示，24/114例（21.1%）患者为局部复发，54/114例（47.4%）为淋巴结转移，75/114例（65.8%）为骨、肺等部位转移。GS/SUV与PSA水平之间存在显著正相关（r = 0.375，r = 0.336，P<0.001）。由于¹⁸F-PSMA-1007 PET/CT检查结果，60/114例（52.6%）患者的治疗决策发生了改变。随访11.0±6.4个月，在¹⁸F-PSMA-1007 PET/CT引导治疗后收集了81/114例患者的PSA数据，其中42/81例（51.9%）患者血清PSA水平下降超过60%。
¹⁸F-PSMA-1007 PET/CT对复发性前列腺癌（PCa）具有较高的病灶检出率，对大多数PCa患者的治疗方案决策可能具有重要意义。
